Jounce Therapeutics (NASDAQ: JNCE) will disclose its first quarter 2022 financial results and provide a corporate update on May 5, 2022. A live conference call, accessible via telephone and webcast, is scheduled for 8:00 a.m. ET. The company is focused on developing novel cancer immunotherapies, with ongoing clinical trials for key product candidates like JTX-8064 and vopratelimab. Jounce aims to transform cancer treatment through a biomarker-driven approach, leveraging its Translational Science Platform to advance multiple development-stage programs.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Raymond James LILRB/ILT Symposium on April 26, 2022, at 1:00 pm ET. The symposium will focus on 'Myeloid Checkpoint' therapeutics in cancer. Jounce is dedicated to developing innovative cancer immunotherapies through a biomarker-driven approach. Its lead program, JTX-8064, targets immune-suppressive tumor-associated macrophages, while other candidates like vopratelimab and pimivalimab are in various stages of clinical trials. For more information, visit www.jouncetx.com.
Jounce Therapeutics (NASDAQ: JNCE) reported its 2021 financial results, highlighting a cash position of $220.2 million as of December 31, 2021. The company is progressing on two clinical trials, INNATE and SELECT, with important data expected in 2022. Revenue recognition decreased to $26.9 million for 2021, down from $62.3 million in 2020, primarily due to reduced collaboration revenue. Net loss for Q4 was $30.2 million, leading to a full-year net loss of $90.9 million. Jounce anticipates a gross cash burn of $115-$130 million for 2022, with sufficient funds to cover expenses into Q3 2023.
Jounce Therapeutics (NASDAQ: JNCE) announced its participation in a novel immuno-oncology panel at the Cowen & Co. 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET. The session will be accessible via webcast on Jounce's website, with a replay available for 30 days post-event. Jounce is focused on developing cancer immunotherapies and currently advancing programs like JTX-8064, a receptor antagonist targeting immune-suppressive tumor macrophages, and vopratelimab, an ICOS-activating monoclonal antibody.
Jounce Therapeutics (NASDAQ: JNCE) will announce its fourth quarter and full year 2021 financial results on March 2, 2022, before market open. The live conference call will start at 8:00 a.m. ET, allowing investors to gain insights into the company's performance and upcoming developments. Jounce is focused on cancer immunotherapy and has ongoing clinical trials, including the Phase 1/2 INNATE trial for JTX-8064, its lead program. It also has licensed GS-1811 to Gilead Sciences, enhancing its strategic partnerships.
Jounce Therapeutics (NASDAQ: JNCE) has announced its participation in two investor conferences in January 2022. The H.C. Wainwright BioConnect Virtual Conference will feature a presentation available on-demand from January 10, 2022, at 7:00 a.m. ET. The 40th Annual J.P. Morgan Healthcare Conference will include a live presentation on January 13, 2022, at 12:00 p.m. ET. Webcasts of both presentations can be accessed via Jounce’s website for 30 days post-event.
Jounce focuses on developing cancer immunotherapies and predictive biomarkers, with key programs including JTX-8064 and vopratelimab in various clinical trials.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in two investor conferences in November 2021. The 5th Annual Cowen IO Next Summit will feature a fireside chat on November 15 at 10:45 a.m. ET, while the 33rd Annual Piper Sandler Healthcare Conference will offer on-demand viewing starting November 22 at 10:00 a.m. ET. Webcasts can be accessed on Jounce's website, with replays available for 30 days. Jounce is focused on developing cancer immunotherapies, including their candidate JTX-8064 and vopratelimab, among others.
Jounce Therapeutics (NASDAQ: JNCE) reported progress in its clinical trials, particularly in the INNATE study of JTX-8064, with active patient recruitment in tumor-specific cohorts. As of September 30, 2021, the company held $249 million in cash and equivalents, up from $213.2 million at the end of 2020. The third quarter net loss was $30.1 million, but the loss per share improved to $0.59 due to an increased number of shares. Jounce projects a cash burn of $100-110 million for 2021 and expects to have around $220 million by year-end.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) will release its third quarter 2021 financial results on November 4, 2021, before the market opens. A live conference call and webcast will follow at 8:00 a.m. E.T. The company focuses on developing cancer immunotherapies and predictive biomarkers, with ongoing programs including JTX-8064 and vopratelimab. Jounce has also licensed GS-1811 to Gilead Sciences. This update is part of Jounce's commitment to transforming cancer treatment with a biomarker-driven approach.
Jounce Therapeutics initiated patient enrollment for tumor-specific expansion cohorts in the ongoing INNATE trial, focusing on JTX-8064 monotherapy and its combination with pimivalimab. Following the completion of dose escalations, this phase aims to address patients previously treated with PD-1 inhibitors and those who are naïve to immuno-oncology treatment. The trial could enroll up to 29 or 47 patients based on pre-specified criteria. Success in these cohorts could lead to rapid progression into registrational trials.